Abstract: The present invention relates to an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1. The present invention also relates to a method for increasing expression of a target protein using the peptide consisting of the amino acid sequence of SEQ ID NO: 1, comprising (a) fusing the peptide with the target protein to form a recombinant protein; and (b) expressing the recombinant protein by an expression host.

Abstract: The present disclosure provides a polynucleotide which is codon optimized for the efficient expression in a eukaryotic cell, a plasmid and a eukaryotic cell comprising the same. The modification resulted in the efficient expression of NIS in eukaryotic cells and the enhancement of the function of NIS by glycosylation. Thus modified polynucleotide encoding NIS of the present disclosure is useful as imaging reporter for gene, viral and/or cell based therapies.

Abstract: The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the DACT1 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing DACT1 gene expression or activity.

Abstract: A short human genomic nucleotide sequence from the SAR3 region of the human interferon ?2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.

Abstract: Ex vivo methods of detecting and analyzing circulating drug metabolites with drug interaction potential are provided. The methods include the use of clinical plasma samples from subjects who have been administered an investigational drug in vivo. The clinical plasma samples will contain both the parent drug and associated metabolites. A control plasma sample spiked directly with the drug of interest can be used as a standard reference. The plasma samples can be applied to an in vitro test system to evaluate the changes in activity or expression of drug-metabolizing enzymes and/or drug transporters in the test systems to determine circulating drug metabolites with drug interaction potential. By comparing the clinical plasma sample to the drug-spiked control, the inhibitory and/or inducing effects on drug-metabolizing enzymes and/or drug transporters can be correctly attributed to the parent drug or its associated metabolites.

Abstract: The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5? shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers.

Abstract: This application provides, in part, pAVEC plasmids and methods of use of such plasmids for the production of polypeptides such as immunoglobulins as well as the generation of recombined versions of such plasmids which contain polynucleotides encoding such polypeptides.

Abstract: The present invention is directed to methods of screening for a small molecule that modulates the ability of a RNA regulatory sequence to inhibit mRNA translation in a mammalian cell comprising incubating the mammalian cell expressing a reporter mRNA and the RNA regulatory sequence in the presence of the small molecule, wherein the RNA regulatory sequence is not attached to the reporter mRNA; and monitoring a reporter protein signal produced by the reporter mRNA, wherein a change in the signal of the reporter protein in the presence of the small molecule compared to the reporter protein signal in the absence of the small molecule indicates the small molecule modulates the ability of the RNA regulatory sequence to inhibit mRNA translation.

Abstract: There is provided an expression vector for animal cell having an increased gene expression efficiency, and particularly, an expression vector for animal cells including a MAR element and a SAR element, which are gene expression increasing factors, at a 5? end of a promoter, a 3? end of a transcription termination site, or at both of the 5? end of the promoter and the 3? end of the transcription termination site. The expression vector for animal cells according to the present invention exhibits remarkably increased gene expression efficiency as compared to conventional expression vectors for animal cells, such that protein expression of foreign genes may be significantly increased using this expression vector for animal cells. Particularly, the expression vector for animal cells according to the present invention may be useful in that a high-expression cell line may be secured even without MTX amplification.

Abstract: The present invention relates to a method to enhance cell growth in culture comprising adding an alkyl-amine-n-oxide (AANOx), such as dodecyldimethylamine oxide (DDAO), into the culture medium in an amount sufficient to improve cell growth.

Abstract: The invention provides compositions and methods for making and using microvascular stamps for stimulation and spatial organization of neovessels in tissue.

Abstract: The invention relates to DNA-sequences, especially transcription- or expression-enhancing elements (TE elements) and their use on an expression vector in conjunction with an enhancer, a promoter, a product gene and a selectable marker. TE elements bring about an increase in the expression of the product gene, particularly when stably integrated in the eukaryotic genome, preferably the CHO-DG44 genome.

Abstract: The present invention is related to an L nucleic acid that binds to an SDF-1.

Abstract: The invention relates to a process for generating fibroblasts, more particularly, to the culturing of fibroblasts in large numbers and of the heterogenic type. The invention is also directed to the use of fibroblasts in the preparation of heterotypic spheroids and a process for the preparation of such heterotypic spheroids.

Abstract: Methods and kits for identifying candidate anti-megakaryocyte agents are disclosed.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.

Abstract: The present invention relates to the propagation of covalently closed circular recombinant DNA molecules such as plasmids, cosmids, bacterial artificial chromosomes (BACs), bacteriophages, viral vectors and hybrids thereof, and more particularly is strain modifications that improve strain viability, plasmid stability, plasmid production yield, and plasmid-directed protein production yield, using said DNA molecules in fermentation culture.

Abstract: The present invention provides a method for controlling hair growth, a method for selecting or evaluating a hair growth control agent, and a hair growth suppression agent. The present invention provides a method for selecting or evaluating a hair growth control agent, including the steps of administering a test substance to a cell capable of expressing DnaJC6; measuring the expression of DnaJC6 in the cell; and evaluating the controlling effect of the test substance on hair growth based on the expression. The present invention also provides a hair growth suppression agent containing funabarasou (Cynanchum atratum) or its extract as the active ingredient.

Abstract: The present invention provides new compositions for transposase-mediated fragmenting and tagging DNA targets. The invention relates to the surprising discovery that use of manganese ions (Mn2+) in transposase reactions improves the transposase reaction. It also relates to the surprising discovery that Mg2+ ions can be used in a transposase reaction with wild-type and/or engineered transposases at levels much higher than previously thought. The invention provides for the use of naturally-occurring transposases in in vitro reactions, as well as improved schemes for cleaving, tagging, and amplifying target DNA.

Abstract: Bioassays for detecting the ability of one sample of a food substance, nutritional supplement, therapeutic agent and/or disease preventive agent relative to that of a second sample of such a substance, supplement and/or agent to inhibit, upregulate or otherwise modulate translation initiation, and thereby demonstrate a disease curative and/or preventive effect in a human and/or animal that consumes a such substance, supplement and/or agent or to whom a such substance, supplement and/or agent is administered are provided.